n,n-dimethylarginine has been researched along with Bright Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bode-Böger, SM; Brilloff, S; Heinrich, A; Hohenstein, B; Hugo, CPM; Jarzebska, N; Martens-Lobenhoffer, J; Rodionov, RN; Todorov, VT; Weiss, N | 1 |
| Baylis, C; Couser, W; Erdely, A; Riggleman, A; Wagner, L | 1 |
| Axelsson, J; Caglar, K; Cakir, E; Carrero, JJ; Eyileten, T; Lindholm, B; Oguz, Y; Qureshi, AR; Saglam, M; Sonmez, A; Stenvinkel, P; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
3 other study(ies) available for n,n-dimethylarginine and Bright Disease
| Article | Year |
|---|---|
ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Topics: Albuminuria; Amidohydrolases; Animals; Arginine; Cell Proliferation; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Down-Regulation; Genetic Predisposition to Disease; Glomerular Mesangium; Glomerulonephritis; Hydrolysis; Kidney; Male; Mice, Inbred C57BL; Mice, Transgenic; Phenotype; Streptozocin | 2017 |
Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis.
Topics: Animals; Antibodies; Arginine; Autoantibodies; Blood Urea Nitrogen; Creatinine; Glomerulonephritis; Kidney Failure, Chronic; Male; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitrites; Proteinuria; Rats; Rats, Sprague-Dawley | 2002 |
ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.
Topics: Adult; Amyloidosis; Arginine; Chronic Disease; Endothelium; Female; Glomerulonephritis; Humans; Male; Multivariate Analysis; Predictive Value of Tests; Proteinuria; Risk Factors | 2008 |